InMode Ltd stock (IL0011356806): Recognized among top aesthetic devices leaders

InMode Ltd continues to rank prominently in the global aesthetic devices market, highlighting its competitive position in minimally invasive treatments amid growing US demand for non-surgical procedures.

InMode Ltd, a leader in energy-based aesthetic devices, was listed among the top 30 companies in the global aesthetic devices market for 2026-2035 by Spherical Insights. This recognition underscores the company's role in powering non-invasive procedures like body contouring and skin tightening, which are increasingly popular among US consumers seeking quick recovery options.

The stock traded at approximately 7.50 USD on Nasdaq on 05/13/2026, reflecting steady interest from US retail investors in medtech firms with strong exposure to the booming aesthetics sector, according to Yahoo Finance as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: InMode Ltd
• Sector/industry: Medical Devices / Aesthetic Technologies
• Headquarters/country: Israel
• Core markets: US, Europe, Asia
• Key revenue drivers: Radiofrequency and laser platforms
• Home exchange/listing venue: Nasdaq (INMD)
• Trading currency: USD

InMode Ltd: core business model

InMode Ltd develops and sells minimally invasive aesthetic medical devices powered by radiofrequency energy. Platforms like Forma, Morpheus8, and Optimas target skin rejuvenation, fat reduction, and women's wellness procedures. The company operates on a razor-and-blade model, selling systems upfront and recurring consumables, which drives predictable revenue. InMode generates over 70% of sales from the US market as of its 2024 annual report published in March 2025, according to InMode investor relations as of 03/2025.

Founded in 2008 and headquartered in Israel, InMode went public on Nasdaq in 2018. It emphasizes FDA-cleared technologies for outpatient settings, appealing to US physicians in dermatology and plastic surgery. This focus positions InMode well for US investors tracking medtech growth in aesthetics, a segment projected to expand with rising demand for non-surgical enhancements.

Main revenue and product drivers for InMode Ltd

InMode's revenue primarily stems from its workstation sales and proprietary handpieces. In Q4 2024, reported February 2025, the company posted $120.5 million in revenue, up 25% year-over-year, driven by US placements of Morpheus8 systems used for microneedling radiofrequency treatments, per InMode press release as of 02/26/2025. Recurring revenue from tips and gels accounted for about 30% of total sales in that period.

Key products include Optimas, a multi-application platform, and Evolve, for hands-free body sculpting. These cater to high-margin procedures in medspas and clinics, with strong US adoption. Spherical Insights ranked InMode among top global players for 2026-2035, citing its innovation in aesthetic devices, according to Spherical Insights as of 2026.

Industry trends and competitive position

The global aesthetic devices market is forecasted to grow at 11% CAGR through 2035, fueled by non-invasive procedures gaining share over surgery. In the US, Botox and fillers dominate, but radiofrequency platforms like InMode's are capturing growth in skin tightening amid aging demographics. Competitors include Allergan Aesthetics and Candela, but InMode differentiates with cost-effective, versatile systems for smaller practices.

InMode holds a solid position in the US medspa channel, which represents over 50% of aesthetics revenue. Its direct sales model and physician training programs support market penetration, relevant for US investors eyeing medtech firms with domestic exposure.

Why InMode Ltd matters for US investors

InMode derives the majority of revenue from the US, where aesthetics spending exceeds $15 billion annually. Nasdaq listing provides liquidity for retail investors, and the company's growth aligns with US trends in elective procedures post-pandemic. Exposure to medspas expanding nationwide enhances its appeal in portfolios focused on healthcare innovation.

Conclusion

InMode Ltd maintains a strong foothold in the aesthetic devices space, as evidenced by its top-30 ranking and consistent US revenue growth. While market expansion offers tailwinds, competition and regulatory factors remain considerations. Investors should monitor upcoming earnings for updates on procedure volumes and international progress.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.